InvestSMART

CSL Limited (ASX:CSL)

ALERT: Price-sensitive ASX Announcement for CSL
Current share price for CSL : $171.570 0.18 (0.11%)+
Announcement
Release
11 Feb 2026 7:46AM
Price at Release
$171.390
Full Release
download
Summary
CSL Limited's Half Year Results Investor Presentation for the financial year 1H26 highlighted several key financial metrics and strategic initiatives. The company reported a total revenue of $8.3 billion, a decline of 4% at constant currency (CC), and an NPATA of $1.9 billion, down by 7%. The report detailed significant restructuring and impairment costs, with a reported NPAT of $401 million, down 81%. CSL maintained a strong balance with cash flows of $1.3 billion and a leverage ratio of 2.0 times. The company expanded its share buyback program from US$500 million to US$750 million. Strategic initiatives included a focus on transformation and growth, with emphasis on expansion in the US and China markets, and leveraging its portfolio in immunoglobulin (Ig) and albumin. The company aimed for a 2-3% revenue growth and a 4-7% NPATA growth in the second half, driven by new product launches and geographic expansion. The report also noted a high level of investment in research and development as well as cost savings from ongoing transformation programs.
Key Points
  • Total revenue for 1H26 was $8.3 billion, a 4% decrease at constant currency.
  • NPATA was $1.9 billion, down 7% from the previous period.
  • Reported NPAT was $401 million, reflecting an 81% decline.
  • Strong cash flow of $1.3 billion and leverage ratio at 2.0x.
  • Expanded share buyback from US$500 million to US$750 million.
  • Focus on transformation and growth initiatives in US and China.
  • Targeted 2-3% revenue growth and 4-7% NPATA growth for 2H26.
  • Significant investment in R&D and cost-saving initiatives.
  • Restructuring and impairment costs impacted financials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.